TO INNOVATIONS

SYMPOSIA SATURDAY 29 OCTOBER 2016
specific interventions to address them is key to tackling drug resistance by improving access and adherence. Lessons learned will be shared,
including successes and failures. Recommendations that are adaptable to other situations will be offered as takeaways for symposium attendees.
Co-chairs: Latha Rajan (United States of America), Sidney Mejia (United States of America)
10.30 Colombia: social factors influencing patient resistance to TB treatment – To be confirmed
10.45 Argentina: relationship of social factors including SES with resistance to TB treatment – To be confirmed
11.00 Haiti: government, institutional, and patient partnerships for TB stigma reduction strategies – To be confirmed
11.15 Mexico: influence of family system dynamics on resistance to DOTS – To be confirmed
11.30 Peru: understanding social support mechanisms to influence health-seeking behaviour, resistance to treatment and overall patient well-being
in TB patients – Carltin Evans (United Kingdom)
11.45 Discussion
SYMPOSIUM 46 3 10:30-12:00 3 SESSION ROOM 13
M. TUBERCULOSIS LOW-LEVEL RESISTANCE:
A CHALLENGE FOR THE LABORATORY, AN OPPORTUNITY FOR MDR- AND XDR-TB TREATMENT
Section: Tuberculosis
Recent genotypic and phenotypic studies have demonstrated that M. tuberculosis drug-resistance can’t be simplified to a susceptible/resistant
dichotomy. Indeed, for many antibiotics, including new drugs such as bedaquiline, some resistant strains display a low level of resistance (LLR)
allowing their use for TB treatment. Such strains are challenging to diagnose by the current drug susceptibility testing methods. Moreover, it appears
that these drug can still have some in vivo activity and, thus, a clinical benefit. The laboratory detection of M. tuberculosis LLR will be reviewed,
as well as the therapeutic opportunities which can be used to treat such strains.
Chair: Alexandra Aubry (France)
10.30 Redefining breakpoints for M. tuberculosis drug resistance – Erik C Boettger (Switzerland)
10.50 Fluoroquinolone low-level resistance: an opportunity for improving XDR-TB treatment – Nicolas Veziris (France)
11.10 Detecting rifampicin low-level resistance: a challenge for the laboratory – Armand van Deun (Belgium)
11.30 Bedaquiline low level resistance: risk factors and clinical impact – Koen Andries (Belgium)
11:50 Discussion
SYMPOSIUM 47 3 13:30-15:00 3 SESSION ROOM 3A
MODELLING TO OVERCOME RESISTANCE TO TB DRUGS AND THE END TB STRATEGY
Section: Tuberculosis
Now that the WHO End TB Strategy and the Stop TB Global Plan to End TB are in place, there is an urgent need to overcome resistance to
TB drugs and to the End TB Strategy and the Global Plan. Mathematical modelling is a critical tool for exploring the health impacts, cost-effectiveness
and resource implications of future TB control options. In this session we present results on five key initiatives helping to overcome
resistance to TB drugs and overcome resistance to achieving the End TB Strategy and Global Plan goals.
Co-chairs: Diana Weil (Switzerland), E Jane Carter (United States of America)
13.30 Cost-effectiveness of triage testing for facility-based systematic screening of tuberculosis in Uganda – Achilles Katamba (Uganda)
13.45 Tradeoffs in new anti-tuberculosis drug introduction policies: a model based analysis – Amber Kunkel (United States of America)
14.00 Capturing in situ fitness costs to drug resistant Mycobacterium tuberculosis in Peru – Gwen Knight (United Kingdom)
14.15 Understanding the contribution of social protection to accelerate TB elimination – Delia Boccia (United Kingdom)
14.30 Illness-related impoverishment averted by TB control: findings for India and South Africa – Stephane Verguet (United States of America)
14.45 Discussion
SYMPOSIUM 48 3 13:30-15:00 3 SESSION ROOM 3B
SHORTENED REGIMENS FOR THE TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS
Section: Tuberculosis
According to the 2015 WHO Global Tuberculosis Report, the proportion of multidrug-resistant tuberculosis (MDR-TB) patients who successfully
completed treatment was only 50 percent. A nine-month MDR-TB regimen piloted in Bangladesh reported 435 (84 percent) successful treatments
out of 515 consecutive MDR-TB patients. This regimen has been introduced in several countries with slight modifications. This symposium aims
to provide updated information on the results and feasibility of the implementation of shortened regimens for MDR-TB treatment.
160 CONFRONTING RESISTANCE: FUNDAMENTALS TO INNOVATION - THE 47 TH UNION WORLD CONFERENCE ON LUNG HEALTH